[A test model for cerebrally-active drugs as demonstrated by the example of the new substance aniracetam].
1-Anisoyl-2-pyrrolidinone (aniracetam, Ro 13-5057) belongs to the group of cyclic GABA-derivatives. The compound showed a protective effect on the central nervous system in animal experiments. This paper reports on a clinical investigation in 60 patients of a geriatric and nursing home. The resocializing and the revitalizing effect were the observed parameters. The criteria were recorded by the physician and the staff. The results show that the evaluations by physicians and nursing staff were in good accordance. Aniracetam was effective with respect to the indication: cerebrovascular insufficiency.
D000368:Aged; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000523:psychology; D003142:Communication; D006801:Humans; D006998:Hypochondriasis / Q000523:psychology; D011596:Psychomotor Disorders / Q000188:drug therapy; D011760:Pyrrolidinones / Q000627:therapeutic use*; D012919:Social Behavior
D011760:Pyrrolidinones; C036466:aniracetam
Ein Testmodell für hirnaktive Pharmaka, aufgezeigt am Beispiel der neuen Substanz Aniracetam.